SURgical interventions with FEIBA (SURF): International registry of surgery in haemophilia patients with inhibitory antibodies

Haemophilia

Volumn 19, Issue 3, 2013, Pages

  Negrier C ^a,b   Lienhart, A ^a   Numerof, R ^c   Stephens, D ^c   Wong, W Y ^c   Baghaei, F ^d   Yee, T T ^e  

^a EDOUARD HERRIOT HOSPITAL   (France)

^b UNIVERSITÉ LYON 1   (France)

^c BAXTER HEALTHCARE CORPORATION   (United States)

^d SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^e ROYAL FREE HOSPITAL   (United Kingdom)

Author keywords

Bypassing therapy; Inhibitors; Perioperative haemostasis; Surgery

Indexed keywords

ACTIVATED PROTHROMBIN COMPLEX; ANTIFIBRINOLYTIC AGENT; AUTOANTIBODY; BLOOD CLOTTING FACTOR 8 ANTIBODY; BLOOD CLOTTING FACTOR 9 ANTIBODY; HEPARIN; TRANEXAMIC ACID; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; ANEMIA; ANTIBODY TITER; ARTERIOVENOUS FISTULA; ARTICLE; BLEEDING; CHILD; CLINICAL ARTICLE; DEEP VEIN THROMBOSIS; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; HEMARTHROSIS; HEMOPHILIA; HEMOPHILIA A; HEMOPHILIA B; HEMOSTASIS; HUMAN; INFANT; MALE; MULTICENTER STUDY; OPEN STUDY; PERIOPERATIVE PERIOD; PRIORITY JOURNAL; PROSPECTIVE STUDY; REGISTER; RISK ASSESSMENT; SUPERFICIAL VEIN THROMBOSIS; SURGICAL PATIENT; THROMBOSIS; TREATMENT OUTCOME; VEIN THROMBOSIS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; AUTOANTIBODIES; BLOOD COAGULATION FACTORS; BLOOD LOSS, SURGICAL; CHILD; CHILD, PRESCHOOL; FACTOR VIII; FEMALE; HEMOGLOBINS; HEMOPHILIA A; HEMOPHILIA B; HEMOSTASIS, SURGICAL; HUMANS; INFANT; ISOANTIBODIES; MALE; MIDDLE AGED; PERIOPERATIVE CARE; REGISTRIES; YOUNG ADULT;

EID: 84876814220     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/hae.12080     Document Type: Article

References (21)

1. Astermark J, Donfield SM, DiMichele DM, et al. A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: the FEIBA NovoSeven Comparative (FENOC) Study. Blood 2007; 109: 546-51.
2. Holme PA, Brosstad F, Tjønnfjord GE. Acquired haemophilia: management of bleeds and immune therapy to eradicate autoantibodies. Haemophilia 2005; 11: 510-5.
3. Sallah S. Treatment of acquired haemophilia with factor eight inhibitor bypassing activity. Haemophilia 2004; 10: 169-73.
4. Ehrlich HJ, Henzl MJ, Gomperts ED. Safety of factor VIII inhibitor bypass activity (FEIBA): 10-year compilation of thrombotic adverse events. Haemophilia 2002; 8: 83-90.
5. Aledort LM. Comparative thrombotic event incidence after infusion of recombinant factor VIIa versus factor VIII inhibitor bypass activity. J Thromb Haemost 2004; 2: 1700-8.
6. Négrier C, Goudemand J, Sultan Y, Bertrand M, Rothschild C, Lauroua P. Multicenter retrospective study on the utilization of FEIBA in France in patients with factor VIII and factor IX inhibitors. French FEIBA Study Group. Factor Eight Bypassing Activity. Thromb Haemost 1997; 77: 1113-9.
7. Quintana-Molina M, Martinez-Bahamonde F, Gonzalez-Garcia E, et al. Surgery in haemophilic patients with inhibitor: 20 years of experience. Haemophilia 2004; 10(Suppl. 2): 30-40.
8. Tjønnfjord GE. Activated prothrombin complex concentrate (FEIBA) treatment during surgery in patients with inhibitors to FVIII/IX: the updated Norwegian experience. Haemophilia 2004; 10(Suppl. 2): 41-5.
9. Tjønnfjord GE, Brinch L, Gedde-Dahl T, Brosstad FR. Activated prothrombin complex concentrate (FEIBA) treatment during surgery in patients with inhibitors to FVIII/IX. Haemophilia 2004; 10: 174-8.
10. Ménart C, Lalain JJ, Lienhart A, Dechavanne M, Négrier C. Safety and efficacy of three arthroscopic procedures using Holmium: Yag laser in two high-responder haemophiliacs. Haemophilia 1999; 5: 278-81.
11. Stine KC, Shrum D, Becton DL. Use of FEIBA for invasive or surgical procedures in patients with severe hemophilia A or B with inhibitors. J Pediatr Hematol Oncol 2007; 29: 216-21.
12. Rodriguez-Merchan EC, Jimenez-Yuste V, Gomez-Cardero P, Alvarez-Roman M, Martin-Salces M, Rodriguez de la Rua A. Surgery in haemophilia patients with inhibitors, with special emphasis on orthopaedics: Madrid experience. Haemophilia 2010; 16: 84-8.
13. Rangarajan S, Yee TT, Wilde J. Experience of four UK comprehensive care centres using FEIBA(R) for surgeries in patients with inhibitors. Haemophilia 2011; 17: 28-34.
14. Kraut EH, Jordan S, Witkoff L, Stanek M. Control of bleeding in patients with inhibitors to factor VIII and IX undergoing surgical procedures. Haemophilia 2004; 10: 60.
15. Lauroua P, Ferrer AM, Guérin V. Successful major and minor surgery using factor VIII inhibitor bypassing activity in patients with haemophilia A and inhibitors. Haemophilia 2009; 15: 1300-7.
16. Ludlam CA, Smith MP, Morfini M, Gringeri A, Santagostino E, Savidge GF. A prospective study of recombinant activated factor VII administered by continuous infusion to inhibitor patients undergoing elective major orthopaedic surgery: a pharmacokinetic and efficacy evaluation. Br J Haematol 2003; 120: 808-13.
17. Dimichele D, Négrier C. A retrospective postlicensure survey of FEIBA efficacy and safety. Haemophilia 2006; 12: 352-62.
18. Luu H, Ewenstein B. FEIBA safety profile in multiple modes of clinical and home-therapy application. Haemophilia 2004; 10(Suppl. 2): 10-6.
19. Teitel JM, Carcao M, Lillicrap D, et al. Orthopaedic surgery in haemophilia patients with inhibitors: a practical guide to haemostatic, surgical and rehabilitative care. Haemophilia 2009; 15: 227-39.
20. Balkan C, Karapinar D, Aydogdu S, et al. Surgery in patients with haemophilia and high responding inhibitors: Izmir experience. Haemophilia 2010; 16: 902-9.
21. Dargaud Y, Lienhart A, Négrier C. Prospective assessment of thrombin generation test for dose monitoring of bypassing therapy in hemophilia patients with inhibitors undergoing elective surgery. Blood 2010; 116: 5734-7.